Literature DB >> 30004074

Renal-type clear cell carcinoma of prostate: A case report and review of literature.

Guangjie Liao1, Xinke Zhang2, Zhongjian Li1, Su Lan1, Miaoli Huang1, Weijian Huang1.   

Abstract

We analyzed the clinicopathological features of renal-type clear cell carcinoma (RTCCC) in the prostate and its diagnosis according to the example in our hospital and review of the literature. Clinicopathological features of RTCCC in the prostate were observed in a patient from our hospital combining with a review of the literature. Microscopically, the tumor was composed of cells with abundant and translucent cytoplasm, arranged in the form of the vesicular nest or glandular structure. Therefore, it was necessary to distinguish between metastatic clear cell renal cell carcinoma and primary RTCCC in the prostate. Immunohistochemistry (IHC) of this case showed tumor cells were positive expression for cytokeratin (CKpan), low-molecular weight cytokeratin, epithelial membrane antigen, and prostate-specific antigen (PSA), P504S, prostate-specific membrane antigen and partial positive expression for vimentin and CD10. The tumor cells displayed negative expression of high molecular weight cytokeratin, cytokeratin 7 (CK7), CK34, PAX8, and renal cell carcinoma. The morphological and immunohistochemical features of this tumor were in correspondence with RTCCC of the prostate. This tumor is a rare variant of the prostate carcinomas. To the best of our knowledge, this type of extrarenal tumor has only been reported in six previous studies. Combination of histology, IHC, imaging, and serum PSA is needed to perform a suitable diagnosis.

Entities:  

Keywords:  Clear cell carcinoma; prostate; prostate specific antigen; renal cell carcinoma; renal-type

Mesh:

Substances:

Year:  2018        PMID: 30004074     DOI: 10.4103/IJPM.IJPM_396_17

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  2 in total

Review 1.  Rare Case of Renal-type Clear Cell Carcinoma of the Prostate and Review of the Literature.

Authors:  Song Iy Han; Sung-Chul Lim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

2.  LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer.

Authors:  Wei Wang; Ying Xie; Fei Chen; Xu Liu; Li-Li Zhong; Hai-Qiang Wang; Qing-Chang Li
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.